Pulmonary Cell News Volume 14.17 | Sep 4 2025

    0
    57







    2025-09-04 | PULCN 14.17


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 14.17 – 4 September, 2025
    TOP STORY

    Clonal Expansion of Alveolar Fibroblast Progeny Drives Pulmonary Fibrosis in Mouse Models

    Through EdU incorporation, genetic lineage tracing, and single cell RNA sequencing, researchers resolve the proliferation dynamics of lung fibroblasts during post-injury fibrogenesis.
    [Journal of Clinical Investigation]

    Abstract
    PUBLICATIONSListed by the impact factor of the journal

    Caspase-9 Activates β-Catenin Signaling to Promote Pulmonary Fibrosis

    Using both bleomycin-induced mouse models and TGF-β-stimulated alveolar epithelial cells, scientists examined the expression, activity, and pathological significance of caspase-9.
    [Journal of Translational Medicine]

    Full Article

    High-Fidelity Cas9-Mediated Targeting of KRAS Driver Mutations Restrains Lung Cancer in Preclinical Models

    Investigators developed a CRISPR-High Fidelity-Cas9-based therapy strategy that can effectively and specifically target KRASG12C and KRASG12D mutants, avoiding KRASWT off-targeting and affecting KRAS downstream pathways, thereby significantly reducing tumorgenicity.
    [Nature Communications]

    Full Article

    5-HT Regulates Resistance to Aumolertinib by Attenuating Ferroptosis in Lung Adenocarcinoma

    Scientists found that HER2 S310F mutation contributes to third-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance, driven by the accumulation of neurotransmitter 5-hydroxytryptamine (5-HT).
    [EMBO Molecular Medicine]

    Full ArticleGraphical Abstract

    Multi-Omics and Single-Cell Insights Reveal a Lysophosphatidic Acid (LPA)-Mediated Resistant Mechanism to Third Generation EGFR-TKI in Non-Small Cell Lung Cancer

    Investigators conducted plasma metabolomics analysis on 216 longitudinal samples from 186 NSCLC patients enrolled in the clinical trial of rezivertinib.
    [Cancer Research]

    Abstract

    EML4-ALK Rearrangement Creates a Distinctive Myeloid Cell-Dominant Immunosuppressive Microenvironment in Lung Cancer

    An IL6R inhibitor transformed the tumor microenvironment in a murine anaplastic lymphoma kinase (ALK)+ lung adenocarcinoma model, shifting it from an immunosuppressive to a T cell–dominant status.
    [Cancer Immunology Research]

    Abstract
    Generate Consistent Airway Organoids With PneumaCultâ„¢
    REVIEWS

    Particulate Matter Air Pollution: Effects on the Respiratory System

    The authors review the epidemiological evidence linking particulate matter exposure and lung diseases including asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, pneumonia, acute respiratory distress syndrome, and lung cancer.
    [Journal of Clinical Investigation]

    Full Article

    Air Pollution and Alveolar Health

    In recent years, evidence has emerged identifying a role in the development and progression of sub-clinical interstitial lung abnormalities as well as progression and risk of exacerbation of fibrotic interstitial lung diseases.
    [European Respiratory Review]

    Full Article
    INDUSTRY AND POLICY NEWS

    Michael J. Welsh, MD, Receives Yergin-New International Prize for Biomedical Research

    The Icahn School of Medicine at Mount Sinai will award its 2025 Yergin-New International Prize for Biomedical Research to Dr. Michael Welsh of the University of Iowa for his pioneering work in cystic fibrosis, which has advanced understanding and treatment of this inherited lung disease.
    [The Icahn School of Medicine at Mount Sinai]

    Press Release

    Lilly’s Olomorasib Receives US FDA’s Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed Metastatic KRASG12C-Mutant Lung Cancers

    Eli Lilly and Company announced that the US FDA has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA for the first-line treatment of patients with unresectable advanced or metastatic NSCLC with a KRASG12C mutation and PD-L1 expression ≥ 50%.
    [Eli Lilly and Company]

    Press Release
    FEATURED EVENT

    4th Chromosomal Instability as a Driver of Human Disease Conference

    October 7-10, 2025
    St. Julian’s, Malta

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Associate – Pulmonary & Critical Care Medicine

    Washington University in St. Louis – Washington, St. Louis, United States

    Research Assistant – Cellular Oncoproteins in Lung and Colon Cancer

    University of Alabama at Birmingham – Birmingham, Alabama, United States

    Assistant Professor – Pulmonary Critical Care Medicine

    Fred Hutchinson Cancer Center – Seattle, Washington, United States

    Researcher – Therapeutic Resistance in Lung Cancer

    Ohio State University – Columbus, Ohio, United States

    Postdoctoral Research Associate – Lung and Mammary Gland

    Princeton University – Princeton, New Jersey, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2